Abstract 5619
Background
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1 (HSV-1), which can be administered intralesionally in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery is not a treatment option in the head and neck region, i.e. due to the location or the size of the tumor, T-VEC therapy can be an elegant alternative to systemic immunotherapy.
Methods
9 patients with melanoma in the head and neck region started treatment with T-VEC monotherapy at the Netherlands Cancer Institute, of which 4 are still currently on treatment. We collected data on response, adverse events (AE) and baseline characteristics. For response evaluation, we used clinical evaluation with photography, 3-monthly PET-CT’s and histological biopsies.
Results
Median age at baseline was 78.3 years. Of the 5 patients who stopped treatment, the median follow-up time was 9.1 months. Of these patients, 3 (60%) had a complete response (CR), 1 (20%) patient had a partial response (PR) and 1 (20%) patient showed progressive disease (PD) as their best response. ORR was 80%. Duration of response varies between 1.6-21.6 months. 2 patients developed distant metastases, 1 during T-VEC treatment and 1 after achieving a CR with a time to progression of 14.2 months. 4 patients are still on treatment today. Grade 1 AE’s occurred in all patients. Mostly, these consisted of fatigue, influenza-like symptoms and injection site pain. PET-CT and histological biopsies proved to be a clinically useful tool to evaluate treatment response for T-VEC monotherapy, confirming pCR or PD to stage IV disease requiring systemic treatment.
Conclusions
ORR for T-VEC monotherapy for melanoma in the head and neck region at our institute was 80% with 60% achieving a CR. This real world data on T-VEC monotherapy in stage IIIB/C-IVM1a unresectable melanoma of the head and neck region demonstrates interesting results and suggests T-VEC is an elegant alternative to systemic therapy in this select elderly and frail patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Franke: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): amgen. M.W.J.M. Wouters: Research grant / Funding (institution): Novartis. W.J. van Houdt: Advisory / Consultancy, Research grant / Funding (institution): amgen. A.C.J. van Akkooi: Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): amgen; Research grant / Funding (institution): BMS; Research grant / Funding (institution): MSD-Merck; Research grant / Funding (institution): Merck-Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3361 - Providing a nurse-led telephone intervention for patients treated with oral anticancer medication: symptom management and adherence monitoring
Presenter: Etienne Minvielle
Session: Poster Display session 3
Resources:
Abstract
3937 - Chronological evaluation of health-related quality of life and physical symptoms in postoperative pancreatic cancer patients up to 12 months
Presenter: Naoko Sato
Session: Poster Display session 3
Resources:
Abstract
5620 - Understanding the patients’ Experiences of Radiation Therapy: A Qualitative Study on Prostate Cancer Patients
Presenter: Sakarias Johansson
Session: Poster Display session 3
Resources:
Abstract
1792 - Effect of Kegel exercises on prevention of urinary and fecal incontinence in patients with prostate cancer undergoing radiotherapy
Presenter: Aydan Uravylioglu
Session: Poster Display session 3
Resources:
Abstract
2169 - The Meaning of Responsibility – a Secondary Analysis of Patients and Caregivers Calls to an Oncology Emergency Telephone
Presenter: Heidi Jacobsen
Session: Poster Display session 3
Resources:
Abstract
4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy
Presenter: Elif Dil
Session: Poster Display session 3
Resources:
Abstract
1981 - Prevention of dental complications in patients with multiple myeloma (MM) receiving bisphosphonates treatment
Presenter: CESCA PUIGMARTI
Session: Poster Display session 3
Resources:
Abstract
2725 - Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients.
Presenter: Marina Bosch - Damas
Session: Poster Display session 3
Resources:
Abstract
5112 - Symptomatic and toxicity management of cancer patients using a telephone support model led by the oncology nurse
Presenter: Gemma Simó
Session: Poster Display session 3
Resources:
Abstract
1365 - Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Presenter: Xiaole HE
Session: Poster Display session 3
Resources:
Abstract